http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010523578-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate | 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010523578-A |
| titleOfInvention | Method for treating Fabry disease using a pharmacological chaperone |
| abstract | The present invention provides a method for treating a Fabry disease patient by determining whether there is an improvement in a surrogate marker associated with Fabry disease after administration of a specific pharmacological chaperone of α-galactosidase A. The method includes administering an effective amount of 1-deoxygalactonojirimycin to an individual, wherein 1-deoxygalactonojirimycin is an amount effective to increase the activity of α-galactosidase A. To α-galactosidase A. The present invention is also a method for monitoring and increasing the therapeutic response of a Fabry disease patient after administration of a specific pharmacological chaperone of α-galactosidase A by assessing the effect on the cytoplasmic staining pattern of cells derived from the patient. Also provided is a method wherein detection of an intracellular staining pattern that is similar to an intracellular staining pattern from a healthy individual is an indication that the individual suffering from Fabry disease is a responder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016117754-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019510030-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7098529-B2 |
| priorityDate | 2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.